首页> 美国卫生研究院文献>BioData Mining >RNSCLC-PRSP software to predict the prognostic risk and survival in patients with resected T1-3N0–2 M0 non-small cell lung cancer
【2h】

RNSCLC-PRSP software to predict the prognostic risk and survival in patients with resected T1-3N0–2 M0 non-small cell lung cancer

机译:RNSCLC-PRSP软件可预测T1-3N0–2 M0非小细胞肺癌切除患者的预后风险和生存

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundThe clinical outcomes of patients with resected T1-3N0–2M0 non-small cell lung cancer (NSCLC) with the same tumor-node-metastasis (TNM) stage are diverse. Although other prognostic factors and prognostic prediction tools have been reported in many published studies, a convenient, accurate and specific prognostic prediction software for clinicians has not been developed. The purpose of our research was to develop this type of software that can analyze subdivided T and N staging and additional factors to predict prognostic risk and the corresponding mean and median survival time and 1–5-year survival rates of patients with resected T1-3N0–2M0 NSCLC.
机译:背景切除的T1-3N0–2M0非小细胞肺癌(NSCLC)患者具有相同的肿瘤淋巴结转移(TNM)阶段,其临床结果各不相同。尽管在许多已发表的研究中已经报道了其他预后因素和预后预测工具,但尚未开发出适用于临床医生的方便,准确和特定的预后预测软件。我们研究的目的是开发这种软件,该软件可以分析细分的T和N分期以及其他因素,以预测T1-3N0切除患者的预后风险以及相应的平均和中位生存时间以及1-5年生存率–2M0 NSCLC。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号